title: [Eligibility of schizophrenia inpatients to participate in clinical trials].
abstract: BACKGROUND
  This study assesses the potential eligibility of patients admitted to a psychiatric hospitalisation unit to take part in the major clinical trials based on schizophrenia treatment in clinical practice (CATIE, CUtLASS and EUFEST).
  
  
  METHODS
  A retrospective evaluation by consulting the medical records of 241 subjects (59.8% males and 40.2% females, mean age 39.7±13.0 years), admitted consecutively over one year to psychiatric hospitalisation unit with a diagnosis of schizophrenia or another psychosis. The influence of the factors involved in the non-eligibility in each of the clinical trials is analysed using logistic regression analysis.
  
  
  RESULTS
  Only 20.7%, 22.3%, and 22.5% of patients with schizophrenia or another psychosis would be eligible to participate in the CATIE, CUtLASS and EUFEST studies, respectively. The main factors involved in the non-eligibility were polytherapy with anti-psychotics (2 or more) (Odds Ratio (OR): 7.64, 95% confidence interval (CI): 3.06-19.06, P<.001), mental retardation (OR: 16.67, 95% CI: 1.75-166.67, P=.014), and resistance, intolerance or contraindication to any of the anti-psychotics of the study (OR: 3.68, 95% CI: 1.13-11.99, P=.030).
  
  
  CONCLUSIONS
  Three out of every four patients with schizophrenia or another psychosis admitted to a psychiatric hospitalisation unit are not represented in the major clinical trials on schizophrenia treatment.
authors.affiliation: Servicio de Salud Mental, Complejo Hospitalario Universitario de Albacete, Grupo de Investigación de Salud Mental en Albacete (ISAMA), Albacete, España.
authors.forename: Eliseo
authors.initials: E
authors.lastname: Iniesta
authors.forename: Marta
authors.initials: M
authors.lastname: Lucas
authors.forename: Juana
authors.initials: J
authors.lastname: Ruiz
authors.forename: María
authors.initials: M
authors.lastname: Portela
authors.forename: Patricia
authors.initials: P
authors.lastname: Romero-Rodenas
authors.forename: M Teresa
authors.initials: MT
authors.lastname: Tolosa
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Díaz
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Martín
authors.forename: Karen
authors.initials: K
authors.lastname: Nieto
authors.forename: M Dolores
authors.initials: MD
authors.lastname: Martínez
authors.forename: Joaquín
authors.initials: J
authors.lastname: Lloret
authors.forename: Angels
authors.initials: A
authors.lastname: Mayordomo
authors.forename: Mar
authors.initials: M
authors.lastname: Domato
authors.forename: David
authors.initials: D
authors.lastname: Fraguas
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D004608:Eligibility Determination; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy